1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors
Condition: Solid Tumors
Sponsor: Mirati Therapeutics, Inc.
Full Title
1719-001: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Study Treatment
Oral PRMT5 inhibitor MRTX1719
Eligibility/Info
Phase 1 - advanced MTAP deleted solid tumor that has continued to grow despite treatment with standard anti-cancer therapies.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
